A new trading day began on Tuesday, with Viridian Therapeutics Inc (NASDAQ: VRDN) stock price down -5.12% from the previous day of trading, before settling in for the closing price of $17.77. VRDN’s price has ranged from $11.40 to $27.20 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -4.19% over the past five years. Meanwhile, its annual earnings per share averaged 24.07%. With a float of $70.47 million, this company’s outstanding shares have now reached $79.18 million.
Let’s look at the performance matrix of the company that is accounted for 96 employees. In terms of profitability, gross margin is -2047.68%, operating margin of -93722.52%, and the pretax margin is -85127.15%.
Viridian Therapeutics Inc (VRDN) Insider and Institutional Ownership
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Viridian Therapeutics Inc is 11.04%, while institutional ownership is 99.00%. The most recent insider transaction that took place on Sep 27 ’24, was worth 117,050. In this transaction Chief Operating Officer of this company bought 5,000 shares at a rate of $23.41, taking the stock ownership to the 6,000 shares. Before that another transaction happened on Sep 27 ’24, when Company’s President and CEO bought 21,400 for $23.33, making the entire transaction worth $499,262. This insider now owns 21,400 shares in total.
Viridian Therapeutics Inc (VRDN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 24.07% per share during the next fiscal year.
Viridian Therapeutics Inc (NASDAQ: VRDN) Trading Performance Indicators
Here are Viridian Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 18.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4451.75.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.31, a number that is poised to hit -1.04 in the next quarter and is forecasted to reach -4.16 in one year’s time.
Technical Analysis of Viridian Therapeutics Inc (VRDN)
Viridian Therapeutics Inc (NASDAQ: VRDN) saw its 5-day average volume 1.62 million, a negative change from its year-to-date volume of 1.66 million. As of the previous 9 days, the stock’s Stochastic %D was 5.98%. Additionally, its Average True Range was 1.22.
During the past 100 days, Viridian Therapeutics Inc’s (VRDN) raw stochastic average was set at 26.14%, which indicates a significant increase from 1.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 57.62% in the past 14 days, which was lower than the 77.56% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.52, while its 200-day Moving Average is $17.40. Nevertheless, the first resistance level for the watch stands at $17.78 in the near term. At $18.70, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.20. If the price goes on to break the first support level at $16.36, it is likely to go to the next support level at $15.86. The third support level lies at $14.94 if the price breaches the second support level.
Viridian Therapeutics Inc (NASDAQ: VRDN) Key Stats
With a market capitalization of 1.34 billion, the company has a total of 79,213K Shares Outstanding. Currently, annual sales are 310 K while annual income is -237,730 K. The company’s previous quarter sales were 90 K while its latest quarter income was -76,690 K.
